Khaled Musallam

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (213)

• 2026 Update on Clinical Trials in β‐Thalassemia
  American Journal of Hematology 2026 DOI: 10.1002/ajh.70472
  +Save
• Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes
  Blood Reviews 2026 DOI: 10.1016/j.blre.2026.101430
  +Save
• Thalassaemia
  Nature Reviews Disease Primers 2026 DOI: 10.1038/s41572-026-00722-w
  +Save
• Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease
  Hemoglobin 2026 DOI: 10.1080/03630269.2026.2682386
  +Save
• Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the BEYOND Trial
  European Journal of Haematology 2026 DOI: 10.1111/ejh.70161
  +Save
• Scientific progress in the shadow of regional instability
  The Lancet Haematology 2026 DOI: 10.1016/S2352-3026(26)00065-7
  +Save
• Achieving clinically meaningful changes in haemoglobin levels in patients with non‐transfusion‐dependent β‐thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial
  British Journal of Haematology 2026 DOI: 10.1111/bjh.70227
  +Save
• Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
  The Lancet Haematology 2026 DOI: 10.1016/S2352-3026(25)00320-5
  +Save
• Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia
  American Journal of Hematology 2026 DOI: 10.1002/ajh.70100
  +Save
• Efficacy and safety of luspatercept in non–transfusion-dependent β-thalassemia: long-term results from the BEYOND study
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2025016554
  +Save